Oncotype DX tumor gene expression profiling in stage II colon cancerApplication: Prognostic, risk prediction | Zendy

Elizabeth M. Webber | Zendy; Jennifer S Lin | Zendy; Evelyn P Whitlock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oncotype DX tumor gene expression profiling in stage II colon cancerApplication: Prognostic, risk prediction

Author(s) -

Elizabeth M. Webber,

Jennifer S Lin,

Evelyn P Whitlock

Publication year - 2010

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1177

Subject(s) - medicine , colorectal cancer , stage (stratigraphy) , risk stratification , oncology , gene expression profiling , disease , bioinformatics , gene , gene expression , cancer , biology , paleontology , biochemistry

Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research